 Regulatory authorities in South Africa have signed off RedHill Biopharma Ltds NASDAQ: RDHL Phase 23 study evaluating RHB-107 upamostat for non-hospitalized patients with symptomatic COVID-19. The study is already ongoing in the U.S., with an expansion of study sites underway to further accelerate recruitment. 